Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015

Print

Search Results for 'Financial Report: Charles River Laboratories'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published February 11, 2015
Discovery and manufacturing services drive growth Read More »
Published October 30, 2014
Argenta and BioFocus acquisition drives growth in the quarter Read More »
Published August 7, 2014
Manufacturing revenue up 18% in the quarter Read More »
By Kristin Brooks
Published February 12, 2014
PCS segment sales up 8% in the quarter Read More »
Published August 1, 2013
Revenues up 3% in the quarter Read More »
Published May 2, 2013
PCS sales up 6% in the quarter Read More »
Published February 14, 2013
Revenues decline 4% in the quarter Read More »
Published August 8, 2012
Foreign exchange impacts sales Read More »
Published February 14, 2012
RMS segment sales were up, while PCS segment sales declined Read More »
Published August 5, 2009
Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand. Read More »
Published February 10, 2009
Preclinical Services (PCS) segment revenue was $158.6 million (-8%) due to slower market demand and the negative impact of foreign exchange. Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On